-
Mashup Score: 79
Blood Cancer Journal – VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44
Blood Cancer Journal – CD56 expression predicts response to Daratumumab-based regimens
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Blood Cancer Journal – Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 50FDA Approves Cilta-Cel for R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy - 8 day(s) ago
The FDA has approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 87
The Committee will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding t…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake - 9 day(s) ago
About 15 years ago, Carl Ola Landgren, M.D. Ph.D., noticed an encouraging yet potentially concerning trend in the treatment of multiple myeloma. | At an FDA advisory committee meeting this Friday, two teams will present their studies examining the utility of minimal residue disease (MRD) as a potentially approvable endpoint in multiple myeloma. For this report, Fierce Pharma spoke with experts to learn about what’s at stake, including the need to bring new treatments to patients earlier.
Source: www.fiercepharma.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 36Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis - PubMed - 10 day(s) ago
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review characterises all published randomised controlled trials (RCTs) in MM using PFS or other TTE end-points between 2005 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the SWOG S0777 and MAIA trials in transplant-ineligible newly diagnosed multiple myeloma in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple Myeloma - 10 day(s) ago
Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis - PubMed - 11 day(s) ago
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review characterises all published randomised controlled trials (RCTs) in MM using PFS or other TTE end-points between 2005 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study https://t.co/Xd7WS4S6ry #mmsm https://t.co/i0jlM4IpMZ